About the Author |
|
xiii | |
Foreword |
|
xv | |
Mass Spectrometry: An Oncologist's Viewpoint |
|
xvii | |
Preface |
|
xix | |
Acknowledgments |
|
xxi | |
Terminology and Abbreviations |
|
1 | (544) |
|
Overview and Scope of Applications |
|
|
5 | (18) |
|
|
5 | (2) |
|
Functions and Types of Instrument Components |
|
|
7 | (8) |
|
Sample Introduction Systems |
|
|
7 | (2) |
|
|
9 | (3) |
|
|
12 | (2) |
|
|
14 | (1) |
|
|
15 | (1) |
|
|
15 | (1) |
|
|
15 | (2) |
|
Resolution and Resolving Power |
|
|
15 | (1) |
|
|
16 | (1) |
|
|
16 | (1) |
|
|
16 | (1) |
|
Specificity Sensitivity and Limit of Detection |
|
|
17 | (1) |
|
Information from Mass Spectra and Scope of Applications |
|
|
17 | (6) |
|
Instrumentation and Techniques of Mass Spectrometry |
|
|
23 | (58) |
|
|
23 | (13) |
|
|
23 | (1) |
|
|
24 | (1) |
|
Atmospheric Pressure Chemical Ionization |
|
|
25 | (1) |
|
|
26 | (3) |
|
|
29 | (1) |
|
Microfabricated Silicone Chip-Based Electrospray Ion Sources |
|
|
29 | (1) |
|
|
29 | (1) |
|
Fast Atom and Ion Bombardment |
|
|
30 | (1) |
|
Matrix-Assisted Laser Desorption Ionization |
|
|
31 | (2) |
|
Surface-Enhanced Laser Desorption Ionization (SELDI) |
|
|
33 | (1) |
|
|
33 | (1) |
|
Direct Laser Desorption Ionization |
|
|
33 | (1) |
|
Resonance-Enhanced Multiphoton Ionization |
|
|
33 | (1) |
|
Inductively Coupled Plasma |
|
|
34 | (1) |
|
Miscellaneous Ionization Techniques |
|
|
34 | (1) |
|
Secondary Ion Mass Spectrometry |
|
|
34 | (1) |
|
Field Ionization and Field Desorption |
|
|
34 | (1) |
|
Californium-252 Plasma Desorption |
|
|
35 | (1) |
|
|
35 | (1) |
|
|
35 | (1) |
|
|
36 | (1) |
|
|
36 | (13) |
|
|
36 | (2) |
|
Orthogonal Acceleration TOF |
|
|
38 | (1) |
|
Reflectrons (Ion Mirrors) |
|
|
38 | (1) |
|
|
39 | (1) |
|
|
39 | (2) |
|
Quadrupoles as Ion Guides |
|
|
41 | (1) |
|
|
41 | (1) |
|
|
41 | (1) |
|
|
42 | (1) |
|
Magnetic Sector and Electrostatic Analyzers |
|
|
42 | (2) |
|
Fourier Transform Ion-Cyclotron Resonance Analyzers |
|
|
44 | (1) |
|
|
45 | (1) |
|
Magnetic Analyzers as Components of Tandem Systems |
|
|
46 | (1) |
|
Quadrupole-Time-of-Flight Hybrid Analyzer |
|
|
47 | (1) |
|
Hexapole-TOF Hybrid Analyzer |
|
|
47 | (1) |
|
Accelerator Mass Spectrometry |
|
|
48 | (1) |
|
|
49 | (3) |
|
Single Point Ion Collectors |
|
|
50 | (1) |
|
|
50 | (1) |
|
Secondary Electron Multipliers |
|
|
50 | (1) |
|
|
50 | (1) |
|
Multipoint (Array) Detectors |
|
|
51 | (1) |
|
Interfaces for Sample Introduction |
|
|
52 | (7) |
|
Gases and Volatile Liquids |
|
|
53 | (1) |
|
Reservoir and Batch Inlets |
|
|
53 | (1) |
|
|
54 | (1) |
|
Static Direct Inlet Probes |
|
|
54 | (1) |
|
Interfaces for Coupling with Gas Chromatographs |
|
|
54 | (1) |
|
Interfaces for Coupling with Liquid Chromatographs |
|
|
55 | (1) |
|
Interfaces for Coupling with Capillary Electrophoresis Systems |
|
|
56 | (2) |
|
High Throughput Inlets and Microfabricated Fluidic Systems |
|
|
58 | (1) |
|
Mass Spectrometry/Mass Spectrometry (MS/MS) |
|
|
59 | (4) |
|
|
59 | (1) |
|
|
60 | (1) |
|
Collision-Induced Dissociation |
|
|
60 | (1) |
|
Electron-Capture Dissociation |
|
|
60 | (1) |
|
Photodissociation and Surface-Induced Dissociation |
|
|
60 | (1) |
|
|
61 | (1) |
|
Tandem-in-Space (Transmission) Techniques |
|
|
61 | (1) |
|
Product-Ion Scanning Mode |
|
|
62 | (1) |
|
|
62 | (1) |
|
Constant Neutral Loss Scanning Mode |
|
|
62 | (1) |
|
Selected Reaction Monitoring |
|
|
62 | (1) |
|
|
62 | (1) |
|
Tandem-in-Time (Trapped-Ion) Techniques |
|
|
63 | (1) |
|
Identification and Quantification |
|
|
63 | (6) |
|
Mass Spectral Libraries and Bioinformatics |
|
|
63 | (1) |
|
Accurate Mass Measurement |
|
|
64 | (1) |
|
Selected Ion and Reaction Monitoring |
|
|
65 | (1) |
|
|
65 | (2) |
|
Selected Reaction Monitoring |
|
|
67 | (1) |
|
|
67 | (2) |
|
|
69 | (12) |
|
Relevant Concepts of Cancer Medicine and Biology |
|
|
81 | (26) |
|
Classification and Epidemiology |
|
|
81 | (4) |
|
|
81 | (1) |
|
|
82 | (1) |
|
Incidence and Distribution of Cancers |
|
|
82 | (1) |
|
|
83 | (2) |
|
Cellular Proliferation and Communication |
|
|
85 | (5) |
|
|
85 | (1) |
|
|
86 | (3) |
|
Cellular Communication and Signal Transduction |
|
|
89 | (1) |
|
Genetic Abnormalities in Cancer |
|
|
90 | (5) |
|
Cancer as a Genetic Disorder of Somatic Cells |
|
|
90 | (1) |
|
|
90 | (1) |
|
|
91 | (3) |
|
|
94 | (1) |
|
Carcinogenesis Requires an Accumulation of Mutations |
|
|
94 | (1) |
|
|
95 | (3) |
|
|
95 | (1) |
|
|
96 | (1) |
|
|
97 | (1) |
|
|
98 | (3) |
|
|
98 | (1) |
|
|
98 | (2) |
|
|
100 | (1) |
|
Functional Status Complications and Causes of Death |
|
|
101 | (1) |
|
Some Pertinent Experimental Methods |
|
|
101 | (6) |
|
|
101 | (1) |
|
Polymerase Chain Reaction |
|
|
102 | (1) |
|
Determination of Clonality |
|
|
102 | (1) |
|
|
103 | (1) |
|
Experimental Mouse Models |
|
|
104 | (1) |
|
|
105 | (2) |
|
Metabolism and Biomarkers of Carcinogens |
|
|
107 | (94) |
|
Classification, Mechanism of Action and Biomarkers |
|
|
107 | (10) |
|
Classification and Risk Assessment |
|
|
107 | (1) |
|
|
108 | (1) |
|
Metabolism Enzymatic Activation and Mechanism of Action |
|
|
109 | (1) |
|
Absorption Distribution and Storage |
|
|
109 | (2) |
|
Key Steps in Chemical Carcinogenesis |
|
|
111 | (1) |
|
Functions of Phase I and II Enzymes |
|
|
112 | (1) |
|
Methodologies for Biomarkers |
|
|
113 | (1) |
|
|
113 | (3) |
|
|
116 | (1) |
|
|
117 | (20) |
|
|
117 | (1) |
|
|
117 | (5) |
|
Risk Assessment of Polycyclic Aromatic Hydrocarbons in Coke Workers |
|
|
122 | (3) |
|
Gasoline and Diesel Exhaust |
|
|
125 | (1) |
|
|
125 | (1) |
|
|
125 | (2) |
|
|
127 | (1) |
|
|
128 | (1) |
|
|
128 | (1) |
|
Ethylene and Propylene Oxides |
|
|
129 | (2) |
|
|
131 | (1) |
|
|
132 | (1) |
|
Styrene and Styrene Oxide |
|
|
133 | (1) |
|
Exposure by Health Care Personnel to Cytotoxic Drugs |
|
|
134 | (3) |
|
Environmental Carcinogens |
|
|
137 | (42) |
|
|
137 | (1) |
|
Quantification of Nicotine and Its Metabolites |
|
|
137 | (5) |
|
Benzene and Polycyclic Aromatic Hydrocarbons |
|
|
142 | (1) |
|
|
143 | (3) |
|
Tobacco-Specific N-Nitrosamines |
|
|
146 | (6) |
|
|
152 | (1) |
|
Gasoline and Diesel Fuels |
|
|
152 | (3) |
|
Polycyclic Aromatic Hydrocarbons |
|
|
155 | (1) |
|
Monitoring Miscellaneous Complex Mixtures |
|
|
156 | (2) |
|
|
158 | (1) |
|
|
158 | (3) |
|
Heterocyclic Aromatic Amines |
|
|
161 | (7) |
|
|
168 | (2) |
|
Polycyclic Aromatic Hydrocarbons |
|
|
170 | (1) |
|
|
170 | (1) |
|
|
171 | (1) |
|
Membrane Inlet Mass Spectrometry |
|
|
171 | (1) |
|
Carcinogen Identification in Well Water by High-Resolution MS |
|
|
172 | (1) |
|
Vinyl Chloride Monomer in Drinking Water |
|
|
173 | (1) |
|
Phenolic Xenoestrogens in Water |
|
|
174 | (1) |
|
Mutagenic Heterocyclic Amines in the Danube River |
|
|
174 | (1) |
|
Polycyclic Aromatic Hydrocarbons in Soils |
|
|
174 | (2) |
|
Composted Municipal Sludge and Compost-Amended Soil |
|
|
176 | (1) |
|
|
176 | (1) |
|
|
177 | (1) |
|
|
177 | (1) |
|
|
178 | (1) |
|
|
179 | (1) |
|
DNA Damage by Radiation and Oxidation |
|
|
179 | (22) |
|
|
180 | (21) |
|
Mechanism of Action and Metabolism of Antineoplastic and Chemopreventive Agents |
|
|
201 | (160) |
|
|
201 | (70) |
|
|
201 | (1) |
|
Cell Kill Hypothesis Classification and Mechanisms of Action |
|
|
201 | (3) |
|
Toxicity Resistance and Combination Chemotherapy |
|
|
204 | (2) |
|
Drug Discovery and Development Clinical Trials |
|
|
206 | (5) |
|
|
211 | (1) |
|
|
211 | (1) |
|
|
211 | (13) |
|
|
224 | (3) |
|
|
227 | (1) |
|
Nonclassic Alkylating Agents |
|
|
228 | (1) |
|
|
229 | (8) |
|
|
237 | (1) |
|
Topoisomerase I Inhibitors |
|
|
238 | (5) |
|
Topoisomerase II Inhibitors |
|
|
243 | (11) |
|
|
254 | (1) |
|
Microtubules and Tubulins |
|
|
254 | (2) |
|
|
256 | (2) |
|
|
258 | (5) |
|
|
263 | (2) |
|
|
265 | (1) |
|
Purine and Pyrimidine Analogs |
|
|
265 | (3) |
|
|
268 | (3) |
|
Opportunistic Fungal Infections |
|
|
271 | (1) |
|
|
271 | (18) |
|
|
271 | (1) |
|
|
271 | (2) |
|
|
273 | (1) |
|
|
273 | (2) |
|
|
275 | (2) |
|
Aromatase Inhibitory Activity of Androgens |
|
|
277 | (1) |
|
|
278 | (1) |
|
|
278 | (10) |
|
|
288 | (1) |
|
Targeted Drug Delivery and Therapy |
|
|
289 | (16) |
|
Drugs Conjugated to Proteins Antibodies or Lipids |
|
|
289 | (1) |
|
|
290 | (9) |
|
Antisense Oligonucleotides |
|
|
299 | (2) |
|
Ras Oncoprotein Inhibitors |
|
|
301 | (1) |
|
Antibody-Directed Enzyme Prodrug Therapy |
|
|
302 | (1) |
|
Miscellaneous Strategies for Targeting |
|
|
302 | (1) |
|
|
302 | (2) |
|
|
304 | (1) |
|
|
304 | (1) |
|
Nutritional and Chemical Prevention |
|
|
305 | (56) |
|
Objectives and Classifications |
|
|
305 | (2) |
|
|
307 | (1) |
|
Multicomponent Analysis in Food |
|
|
308 | (4) |
|
Multicomponent Analysis in Body Fluids |
|
|
312 | (4) |
|
Metabolism and Antineoplastic Effects |
|
|
316 | (5) |
|
|
321 | (1) |
|
|
321 | (1) |
|
|
321 | (1) |
|
Terpenes and Ginsenosides |
|
|
322 | (1) |
|
|
322 | (3) |
|
|
325 | (1) |
|
|
325 | (2) |
|
Sulfur-Containing Compounds |
|
|
327 | (1) |
|
|
327 | (2) |
|
|
329 | (1) |
|
Oltipraz and N-acetylcysteine |
|
|
330 | (1) |
|
Retinoids, Vitamins, and Selenium |
|
|
331 | (1) |
|
|
331 | (1) |
|
|
332 | (1) |
|
|
333 | (1) |
|
|
333 | (28) |
|
Strategies Techniques and Applications in Cancer Biochemistry and Biology |
|
|
361 | (184) |
|
|
361 | (99) |
|
|
361 | (1) |
|
Proteomics and Strategies of Proteome Analysis |
|
|
361 | (4) |
|
Protein Isolation Digestion and Delivery into the Ion Source Instrumentation |
|
|
365 | (4) |
|
Sequencing by Edman Degradation |
|
|
369 | (1) |
|
Mass Spectrometric Peptide Mapping |
|
|
370 | (1) |
|
Peptide Ladder Sequencing |
|
|
371 | (1) |
|
Sequencing by Tandem Mass Spectrometry |
|
|
372 | (5) |
|
Protein Identification by Database Searches |
|
|
377 | (4) |
|
Mass Measurement of Intact Proteins |
|
|
381 | (2) |
|
|
383 | (2) |
|
Posttranslational Modifications |
|
|
385 | (2) |
|
|
387 | (8) |
|
Selected Other Posttranslational Modifications |
|
|
395 | (3) |
|
|
398 | (1) |
|
|
398 | (4) |
|
|
402 | (1) |
|
Non-Glycosylated Cytokines |
|
|
403 | (4) |
|
Tumor-Associated Proteins |
|
|
407 | (1) |
|
|
407 | (2) |
|
|
409 | (9) |
|
|
418 | (6) |
|
Genitourinary Malignancies |
|
|
424 | (4) |
|
Gastrointestinal Malignancies |
|
|
428 | (6) |
|
|
434 | (3) |
|
Peptides and Class I Major Histocompatibility Complexes |
|
|
437 | (1) |
|
|
437 | (3) |
|
Strategies and Techniques |
|
|
440 | (2) |
|
Peptide Antigens in Malignancies |
|
|
442 | (7) |
|
Noncovalent Interactions and Protein Folding |
|
|
449 | (1) |
|
Protein-Ligand Interactions |
|
|
449 | (1) |
|
Protein-Protein Interactions |
|
|
450 | (3) |
|
|
453 | (2) |
|
Protein Conformation and Folding |
|
|
455 | (5) |
|
|
460 | (12) |
|
|
462 | (6) |
|
|
468 | (2) |
|
|
470 | (1) |
|
Platelet-Activating Factor |
|
|
471 | (1) |
|
Oligonucleotides and Nucleic Acids |
|
|
472 | (14) |
|
|
472 | (1) |
|
Nomenclature of Fragmentation |
|
|
472 | (1) |
|
|
473 | (1) |
|
|
474 | (1) |
|
High-Resolution MALDI-FTICRMS |
|
|
474 | (1) |
|
Analysis of Large Nucleic Acids |
|
|
475 | (1) |
|
Techniques and Strategies |
|
|
475 | (1) |
|
Polymerase Chain Reaction |
|
|
475 | (1) |
|
|
476 | (1) |
|
Mass Spectrometric Methods for Genotyping |
|
|
476 | (4) |
|
|
480 | (1) |
|
DNA Sequencing and Genetic Diagnosis |
|
|
480 | (1) |
|
Sequencing Exons of the p53 Gene |
|
|
480 | (1) |
|
Identifying Microsatellite Alleles |
|
|
481 | (1) |
|
Familial Adenomatous Polyposis |
|
|
482 | (1) |
|
Multiple Endocrine Neoplasia Type 2A |
|
|
483 | (2) |
|
Breast Cancer Susceptibility Gene BRCA1 |
|
|
485 | (1) |
|
Carbohydrates and Glycoconjugates |
|
|
486 | (59) |
|
|
486 | (1) |
|
Nomenclature and Techniques for Collision-Induced Dissociation |
|
|
486 | (2) |
|
|
488 | (1) |
|
Polysaccharides and Glycosaminoglycans |
|
|
488 | (1) |
|
|
489 | (2) |
|
|
491 | (1) |
|
|
492 | (7) |
|
|
499 | (4) |
|
Miscellaneous Glycoproteins |
|
|
503 | (6) |
|
Glycolipids (Gangliosides) in Various Malignancies |
|
|
509 | (9) |
|
|
518 | (1) |
|
|
518 | (27) |
Index |
|
545 | |